A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease
Ended Cooperative Agreement Awarded Last action
- Award ID
- UG3NS134781
- Recipient
-
IHP Therapeutics Inc. UEI MASZJLS7DHK3
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,767,210
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Place of performance
- California, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $2,589,070 | |
| Amendment | $2,589,070 | |
| Original award | $2,589,070 |
Quick answers
Who received award UG3NS134781?
UG3NS134781 was awarded to IHP Therapeutics Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 18, 2023.
How much is award UG3NS134781 worth?
$7,767,210 has been obligated on UG3NS134781.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award